Approval and human safety

Does MOTS-c improve human strength?

Extra MOTS-c improved running, grip strength and gait in mice. A separate mouse and laboratory study identified CK2 as a direct target and reduced muscle wasting during immobilisation. Human treatment trials here have not established a strength benefit. A functional test in people has to precede a convincing human performance claim for the molecule.

MOTS-c adverse effects

The absence of completed human treatment trials leaves the adverse-effect profile unresolved. The dialysis study measured naturally present MOTS-c; nobody received extra. It therefore cannot provide a side-effect list for taking it. Human absorption, clearance and effects at different amounts also remain unvalidated.

MOTS-c lacks FDA approval for human use, and elite sport restricts it. A research label offers no assurance about identity, strength, impurities or sterility.

Has a human MOTS-c injection routine been established?

No validated human routine emerges from the studies discussed here. Animal regimens describe experimental methods, and the human observational studies concern blood measurements. Turning those into a human schedule would require information the evidence lacks. This site provides no injection or dose instructions.

Does AOD-9604 actually work for weight loss?

Human obesity trials failed to establish a statistically significant weight benefit over placebo. Obese mice did show increased fat oxidation and weight loss, which explains the original interest. The human tolerability programme reported side effects similar to placebo across about 900 participants in roughly six studies. Tolerability and efficacy are separate outcomes.

The rabbit cartilage study concerned experimentally induced osteoarthritis, with lower damage scores over 4 to 7 weeks. Human joint-repair benefit remains unproved. AOD-9604 lacks FDA approval and is prohibited in sport as a growth-hormone fragment.

How does retatrutide work?

It acts at receptors for GIP, GLP-1 and glucagon. The structural and cell experiments confirm engagement of those three targets. The combination affects appetite, glucose-dependent insulin release and fuel handling. I think the human trials earn more attention than the elegance of the design: they measured weight, blood glucose, liver fat and adverse events.

Is retatrutide FDA approved?

Retatrutide lacks FDA approval and remains investigational, with phase 3 testing underway. The phase 2 obesity result was -24.2% mean body-weight change at the highest amount over 48 weeks, versus -2.1% with placebo. Gastrointestinal effects and a dose-dependent heart-rate rise accompanied the weight findings. Longer-term safety and outcomes after treatment remain unsettled.

Why are there no mixing instructions?

The clinical trials used controlled investigational material and medical supervision. An outside preparation has unconfirmed contents, strength, impurities and sterility. A published trial cannot resolve those uncertainties for a particular bottle. I cannot inspect somebody’s material, assess their medical situation or establish a safe way to use an unknown preparation.